SYNTHETIC BIOLOGICS, INC. (NYSEMKT:SYN) Files An 8-K Other Events
Item 8.01.Other Events
On May 11, 2017, Synthetic Biologics, Inc., a Nevada corporation,
(the Registrant) issued the attached press release that included
notification that the U.S. Food and Drug Administration (FDA) has
granted a Breakthrough Therapy Designation for SYN-004
(ribaxamase) for the prevention of Clostridium difficile
infection. A copy of the press release is attached as Exhibit
99.1 to this Report on Form 8-K and incorporated herein by
reference.
Item 9.01.Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |
| 99.1 | Synthetic Biologics, Inc. press release dated May 11, 2017 |
About SYNTHETIC BIOLOGICS, INC. (NYSEMKT:SYN)
Synthetic Biologics, Inc. is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD). Its other product candidates include SYN-007, SYN-006, SYN-005, SYN-200 and SYN-020. The Company is also developing preclinical-stage monoclonal antibody therapies for the prevention and treatment of pertussis, and discovery-stage biotherapeutics for the treatment of phenylketonuria (PKU). SYNTHETIC BIOLOGICS, INC. (NYSEMKT:SYN) Recent Trading Information
SYNTHETIC BIOLOGICS, INC. (NYSEMKT:SYN) closed its last trading session up +0.023 at 0.538 with 2,139,166 shares trading hands.